Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News AnaptysBio Inc ANAB

Healthcare Biotechnology
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ANAB)

Actym Therapeutics Appoints Thomas Smart as CEO

PR Newswire 8 days ago

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire March 11, 2024

Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting

GlobeNewswire February 29, 2024

Anaptys to Present at Guggenheim's 6th Annual Biotechnology Conference

GlobeNewswire January 31, 2024

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

GlobeNewswire November 27, 2023

Anaptys Named a BioSpace 2024 Best Places to Work Winner

GlobeNewswire November 7, 2023

Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 2, 2023

Anaptys Announces Participation in November Investor Conferences

GlobeNewswire November 1, 2023

Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress

GlobeNewswire October 11, 2023
View More News ››

Opinion & Analysis (NDAQ:ANAB)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ANAB)

5 PROMISING STOCKS IN ALOPECIA AREATA

5 PROMISING STOCKS IN ALOPECIA AREATA   1 In 5 Americans Are Losing Their Hair... More than 50 percent of women experience...
AviseAnalytics - July 7, 2021
View more Bullboard ››

Benton Resources Inc.

Benton Resources Inc.

Benton Resources Inc. is a mineral exploration company listed on the TSX Venture Exchange under the symbol BEX. Benton has a ...
View More »